CP
ADPT icon

CenterBook Partners’s Adaptive Biotechnologies ADPT Stock Holding History

CenterBook Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,485
Closed -$270K – 380
2022
Q1 		$270K Buy
+19,485
New +$306K 0.1% 294

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

CenterBook Partners's ADPT Position: Q2 2022 in Review

CenterBook Partners sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 19,485 shares — an estimated $270K sold.

CenterBook Partners first reported a position in ADPT in Q1 2022 and held it in 1 quarter. The position peaked at $270K in Q1 2022. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

  • CenterBook Partners reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
  • CenterBook Partners sold 19,485 Adaptive Biotechnologies shares in Q2 2022, an estimated $270K.
  • CenterBook Partners first reported a position in Adaptive Biotechnologies in Q1 2022 and held it in 1 quarter.
  • CenterBook Partners's Adaptive Biotechnologies position peaked at $270K in Q1 2022.
  • 209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on CenterBook Partners's 13F filing for Q2 2022, filed 15 Aug 2022.